Observational studyInternational journal of clinical oncology2026
Germline pathogenic variants in Japanese adolescents and young adults with advanced solid tumors: a nationwide tumor-normal paired sequencing study.
Observational study in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdolescents and young adults (AYA) aged 15 to 39 years with cancer have a higher prevalence of germline pathogenic variants than older patients. This study characterized the prevalence and distribution of germline pathogenic/likely pathogenic variants (GPVs) in Japanese AYA with advanced solid tumors using nationwide real-world paired tumor and normal sequencing data.
methodsThis retrospective study was conducted using a nationwide cancer genomics database in Japan. In total, 359 AYA with solid tumors who underwent comprehensive genomic profiling with a paired tumor and normal samples between June 2019 and December 2023 were included. The analyses were restricted to 39 genes for which germline findings, defined as variants detected in the matched normal sample within genes eligible for germline disclosure in Japan, are clinically reportable.
resultsAmong 359 patients with advanced solid tumors, GPVs were identified in 32 patients, corresponding to a prevalence of 8.9%. Variants in the TP53 and BRCA2 genes were the most frequently identified. Notably, 13 of 32 cases were identified in an off-tumor context. In lung cancer, GPVs were identified in TP53 and BRCA2, indicating that GPVs in established cancer-predisposition genes can also be detected in tumor types not classically associated with these hereditary cancer genes. In univariable analysis, a family history of cancer and double cancer were associated with GPV positivity.
conclusionsThis national paired tumor and normal sequencing study in Japanese AYA with cancer, identified GPVs including those detected in off-tumor contexts. Germline findings may warrant consideration beyond conventional approaches based on tumor type.
Indexed as
Identifiers
42509448What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.